All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
The vector of anti-CD70 chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target Human CD70. The T cells are genetically modified through transduction with a lentiviral vector expressing scFv of anti-CD70 antibody linked to 41BB and CD3ζ signaling domains. And the vector product was designed for the treatment of Renal cell carcinoma.
CAR Construction : 1F6-CD28-CD3ζ, 1F6-41BB-CD3ζ, 1F6-CD27-CD3ζ Fig.1 In vitro cytotoxicity of CAR cells. A chromium-51 release assay was used to determine antigen-dependent lysis of CD70-CAR T cells against CD70-positiveAML cell lines(Molm-13, THP-1) and KG-1a (CD70−) cells. Sauer, T., Parikh, K., Sharma, S., Omer, B., Sedloev, D., Chen, Q., ... & Rooney, C. M. (2021). CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity. Blood, 138(4), 318-330. |
CAR Construction : 1F6-CD28-CD3ζ, 1F6-41BB-CD3ζ, 1F6-CD27-CD3ζ Fig.2 Determination of cytokines release. Cytokine production by CD70-CAR and NT T cells after antigen stimulation was determined with the multiplex detection assay. Sauer, T., Parikh, K., Sharma, S., Omer, B., Sedloev, D., Chen, Q., ... & Rooney, C. M. (2021). CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity. Blood, 138(4), 318-330. |
CAR Construction : 1F6-CD28-CD3ζ, 1F6-41BB-CD3ζ, 1F6-CD27-CD3ζ Fig.3 Analysis of T-cell exhaustion. Expression of LAG-3, TIM-3 and PD-1, markers associated with T-cell exhaustion on CD70-CAR T cells after antigen stimulation. Sauer, T., Parikh, K., Sharma, S., Omer, B., Sedloev, D., Chen, Q., ... & Rooney, C. M. (2021). CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity. Blood, 138(4), 318-330. |
CAR Construction : 1F6-CD28-CD3ζ, 1F6-41BB-CD3ζ, 1F6-CD27-CD3ζ Fig.4 Antitumor response of CAR-T cells in vivo. Anti-leukemic activity of CD70-CAR T cells in murine AML xenograft model. CD70-CAR T cells were injected 4 days after engraftment of luciferase-labeled Molm-13 cells. Sauer, T., Parikh, K., Sharma, S., Omer, B., Sedloev, D., Chen, Q., ... & Rooney, C. M. (2021). CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity. Blood, 138(4), 318-330. |
CAR Construction : 1F6-CD28-CD3ζ, 1F6-41BB-CD3ζ, 1F6-CD27-CD3ζ Fig.5 Expansion and trafficking of CD70-CAR T cells in vivo. NSG mice underwent AML engraftment with Molm-13 cells and injection of CD70-CAR or NT T cells genetically modified to express a luciferase-GFP fusion protein 4 days later. T-cell expansion and trafficking were monitored by BLI. Sauer, T., Parikh, K., Sharma, S., Omer, B., Sedloev, D., Chen, Q., ... & Rooney, C. M. (2021). CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity. Blood, 138(4), 318-330. |
More Published Data More Published Data
There are currently no customer reviews or questions for Anti-CD70 (1F6) h(41BB-CD3ζ) CAR, pCDCAR1 (CAR-ZP6606). Click the button below to contact us or submit your feedback about this product.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION